4.6 Article

Impact of Pulmonary Function Measurements on Long-Term Survival After Lobectomy for Stage I Non-Small Cell Lung Cancer

Journal

ANNALS OF THORACIC SURGERY
Volume 100, Issue 1, Pages 271-277

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.athoracsur.2015.02.076

Keywords

-

Funding

  1. National Institutes of Health
  2. Duke Tumor Registry

Ask authors/readers for more resources

Background. Pulmonary function tests predict respiratory complications after lobectomy. We evaluated the impact of pulmonary function measurements on longterm survival after lobectomy for stage I non-small cell lung cancer. Methods. The relationship between percent predicted forced expiratory volume in 1 second (FEV1) and percent predicted diffusing capacity of the lung for carbon monoxide (DLCO) and overall survival for patients who underwent lobectomy without induction therapy for stage I (T1-2N0M0) non-small cell lung cancer from 1996 to 2012 was evaluated using the Kaplan-Meier approach and a multivariable Cox proportional hazard model. Results. During the study period, 972 patients (mean DLCO 76 +/- 21, mean FEV1 73 +/- 21) met inclusion criteria. Perioperative mortality was 2.6% (n = 25). The 5-year survival of the entire cohort was 60.1%, with a median follow-up of 43 months. The 5-year survival for patients with percent predicted FEV1 stratified by more than 80%, 61% to 80%, 41% to 60%, and 40% or less was 70.1%, 59.3%, 52.5%, and 53.4%, respectively. The 5-year survival for patients with percent predicted DLCO stratified by more than 80%, 61% to 80%, 41% to 60%, and 40% or less was 70.2%, 63.4%, 44.2%, and 33.1%, respectively. In multivariable survival analysis, both larger tumor size (hazard ratio 1.15, p = 0.01) and lower DLCO (hazard ratio 0.986, p < 0.0001) were significant predictors of worse survival. The association of FEV1 and survival was not statistically significant (p = 0.18). Conclusions. Survival after lobectomy for patients with stage I non-small cell lung cancer is impacted by lower DLCO, which can be used in the risk and benefit assessment when choosing therapy. (C) 2015 by The Society of Thoracic Surgeons

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available